Publications (original articles or review articles) published in 2022 from OUS - Section for head and neck oncology
16 publications found
A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire
Qual Life Res, 32 (2), 447-459
DOI 10.1007/s11136-022-03272-2, PubMed 36273365
Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure
J Patient Rep Outcomes, 6 (1), 26
DOI 10.1186/s41687-022-00434-1, PubMed 35348945
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
J Clin Oncol, 40 (21), 2321-2332
DOI 10.1200/JCO.21.02198, PubMed 35333599
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
J Clin Oncol, 41 (4), 790-802
DOI 10.1200/JCO.21.02508, PubMed 36219809
Community-Based Interventions After Acquired Brain Injury-A Systematic Review of Intervention Types and Their Effectiveness
J Head Trauma Rehabil, 37 (5), E355-E369
DOI 10.1097/HTR.0000000000000765, PubMed 35125426
Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy
J Cancer Surviv, 17 (4), 1082-1093
DOI 10.1007/s11764-022-01273-1, PubMed 36350483
Proteomic Profiling of Saliva and Tears in Radiated Head and Neck Cancer Patients as Compared to Primary Sjögren's Syndrome Patients
Int J Mol Sci, 23 (7)
DOI 10.3390/ijms23073714, PubMed 35409074
Body image concerns in long-term head and neck cancer survivors: prevalence and role of clinical factors and patient-reported late effects
J Cancer Surviv, 17 (2), 526-534
DOI 10.1007/s11764-022-01311-y, PubMed 36509859
Bone mineral density and nutrition in long-term survivors of childhood brain tumors
Clin Nutr ESPEN, 50, 162-169
DOI 10.1016/j.clnesp.2022.05.025, PubMed 35871919
Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017
Pediatr Blood Cancer, 69 (9), e29736
DOI 10.1002/pbc.29736, PubMed 35570402
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Neuro Oncol, 24 (5), 755-767
DOI 10.1093/neuonc/noab243, PubMed 34672349
cAMP-Mediated Autophagy Promotes Cell Survival via ROS-Induced Activation of PARP1: Implications for Treatment of Acute Lymphoblastic Leukemia
Mol Cancer Res, 20 (3), 400-411
DOI 10.1158/1541-7786.MCR-21-0652, PubMed 34880123
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Oral Oncol, 128, 105815
DOI 10.1016/j.oraloncology.2022.105815, PubMed 35381576
Oral and dental late effects in long-term survivors of childhood embryonal brain tumors
Support Care Cancer, 30 (12), 10233-10241
DOI 10.1007/s00520-022-07405-8, PubMed 36307656
Taste and smell function in long-term survivors after childhood medulloblastoma/CNS-PNET
Support Care Cancer, 30 (7), 6155-6162
DOI 10.1007/s00520-022-07048-9, PubMed 35426047
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420